Skip header and navigation

Refine By

5 records – page 1 of 1.

A 10-year retrospective study of interhospital patient transport using inhaled nitric oxide in Norway.

https://arctichealth.org/en/permalink/ahliterature269280
Source
Acta Anaesthesiol Scand. 2015 May;59(5):648-53
Publication Type
Article
Date
May-2015
Author
C. Buskop
P P Bredmose
M. Sandberg
Source
Acta Anaesthesiol Scand. 2015 May;59(5):648-53
Date
May-2015
Language
English
Publication Type
Article
Keywords
Administration, Inhalation
Adolescent
Adult
Aged
Bronchodilator Agents - administration & dosage - adverse effects - therapeutic use
Child
Child, Preschool
Critical Care
Equipment Failure - statistics & numerical data
Extracorporeal Membrane Oxygenation
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
Nitric Oxide - administration & dosage - adverse effects - therapeutic use
Norway
Respiratory Insufficiency - mortality - therapy
Retrospective Studies
Survival Analysis
Tertiary Care Centers
Transportation of Patients
Treatment Outcome
Young Adult
Abstract
Anaesthesiologists from Oslo University Hospital have transported patients with severe oxygenation failure with inhaled nitric oxide (usually 20?ppm) from other hospitals to a tertiary care centre since 2002 in an effort to reduce the number of patients that otherwise would require transport with ongoing extracorporeal membrane oxygenation. The aim of this study was to evaluate the patient safety during transport with inhaled nitric oxide.
All patient transports with ongoing nitric oxide treatment undertaken from 2003 to 2012 were identified in the transport database. The frequency of adverse events and their impact on patient safety were studied in addition to response to inhaled nitric oxide and adjusted intensive care treatment and time aspects of the transports. Information about in-hospital treatment and survival were extracted from the hospital patient records.
Adverse events were recorded in 12 of the 104 transports. Seven of the adverse events were due to malfunctioning technical equipment, three were related to medication other than the inhaled nitric oxide and two were related to ventilation. No adverse events resulted in permanent negative patient consequences or in discontinuation of the transport. Out of 104 patients, 79 responded to treatment with inhaled nitric oxide and other treatment changes by an increase in oxygen saturation of more than 5%. The 30-day mortality was 27% in the group transported with inhaled nitric oxide.
Transporting patients on inhaled nitric oxide is an alternative in selected patients who would otherwise require extracorporeal membrane oxygenation during transport.
PubMed ID
25782015 View in PubMed
Less detail

Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.

https://arctichealth.org/en/permalink/ahliterature175801
Source
Can J Physiol Pharmacol. 2005 Jan;83(1):8-13
Publication Type
Article
Date
Jan-2005
Author
Don D Sin
S F Paul Man
Author Affiliation
Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada. dsin@mrl.ubc.ca
Source
Can J Physiol Pharmacol. 2005 Jan;83(1):8-13
Date
Jan-2005
Language
English
Publication Type
Article
Keywords
Bronchodilator Agents - administration & dosage - adverse effects - therapeutic use
Canada - epidemiology
Cardiovascular Diseases - epidemiology - etiology
Humans
Pulmonary Disease, Chronic Obstructive - complications - drug therapy - epidemiology
Risk factors
Abstract
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in Canada and elsewhere. It affects 5% of all adult Canadians and is the fourth leading cause of death. Interestingly, the leading causes of hospitalizations and mortality among COPD patients are cardiovascular events. In the Lung Health Study, over 5 800 patients with mild to moderate COPD were studied. Forty-two to 48% of all hospitalizations that occurred over the study's 5-year follow-up period were related to cardiovascular complications. Various population-based studies suggest that independent of smoking, age, and gender, COPD increases the risk of cardiovascular morbidity and mortality twofold. Alarmingly, some bronchodilators, which are commonly used to treat symptoms in COPD, may increase the risk of cardiovascular morbidity and even mortality among COPD patients. In this paper, we discuss the epidemiologic evidence linking COPD and cardiovascular events as well as the potential mechanism(s) which may be responsible for this association.
PubMed ID
15759045 View in PubMed
Less detail

Efficacy and safety of fluticasone furoate 100 µg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial.

https://arctichealth.org/en/permalink/ahliterature258341
Source
Respir Med. 2014 Jan;108(1):41-9
Publication Type
Article
Date
Jan-2014
Author
Jan Lötvall
Eugene R Bleecker
William W Busse
Paul M O'Byrne
Ashley Woodcock
Edward M Kerwin
Sally Stone
Richard Forth
Loretta Jacques
Eric D Bateman
Author Affiliation
Krefting Research Centre, University of Gothenburg, Box 424, SE 40530 Gothenburg, Sweden. Electronic address: jan.lotvall@gu.se.
Source
Respir Med. 2014 Jan;108(1):41-9
Date
Jan-2014
Language
English
Publication Type
Article
Keywords
Administration, Inhalation
Adult
Androstadienes - administration & dosage - adverse effects - therapeutic use
Asthma - drug therapy
Bronchodilator Agents - administration & dosage - adverse effects - therapeutic use
Double-Blind Method
Drug Administration Schedule
Female
Great Britain
Humans
Male
Middle Aged
Ontario
South Africa
Sweden
Treatment Outcome
United States
Abstract
Inhaled corticosteroids (ICSs) improve asthma disease control; once-daily ICS administration may have advantages for patients. Our objective was to assess the efficacy and safety of the novel ICS fluticasone furoate (FF) over 24 weeks versus placebo. This was a 24-week double-blind, double-dummy, placebo- and active-controlled study (NCT01159912) of 343 asthma patients (=12 years) not controlled by their current ICS. Patients were randomised (1:1:1) to FF100 µg, placebo (both administered once-daily [OD] via ELLIPTA™ dry powder inhaler in the evening) or fluticasone propionate (FP) 250 µg (administered twice-daily (BD) via DISKUS™/ACCUHALER™). Primary endpoint was change from baseline in pre-dose evening forced expiratory volume in 1s (FEV1) at Week 24; change from baseline in % rescue-free 24-h periods was a powered secondary endpoint. Adverse events (AEs) were assessed. FF100 µg OD and FP250 µg BD significantly improved pre-dose evening FEV1 compared with placebo at Week 24 (+146 ml [p = 0.009] and +145 ml [p = 0.011], respectively). Percentage of rescue-free 24-h periods was increased with FF100 µg OD (+14.8%) and FP250 µg BD (+17.9%) compared to placebo (both p 
PubMed ID
24295556 View in PubMed
Less detail

Nebulizers: the patient and the prescription.

https://arctichealth.org/en/permalink/ahliterature254789
Source
Can Med Assoc J. 1973 Mar 17;108(6):692-3
Publication Type
Article
Date
Mar-17-1973
Author
P. Barsky
Source
Can Med Assoc J. 1973 Mar 17;108(6):692-3
Date
Mar-17-1973
Language
English
Publication Type
Article
Keywords
Aerosol Propellants
Aerosols
Asthma - drug therapy
Bronchodilator Agents - administration & dosage - adverse effects - therapeutic use
Canada
Chlorofluorocarbons, Methane - adverse effects
Drug Prescriptions
Humans
Isoproterenol - administration & dosage - adverse effects - therapeutic use
Legislation, Drug
Substance-Related Disorders
Notes
Cites: Ann Intern Med. 1966 Nov;65(5):985-955923100
Cites: Br Med J. 1968 Feb 10;1(5588):335-95317525
Cites: JAMA. 1970 Jun 22;212(12):2075-95467774
Cites: J Allergy. 1969 Feb;43(2):101-135249444
PubMed ID
4691102 View in PubMed
Less detail

[The efficacy of tiotropium bromide (spiriva) in the treatment of patients with chronic obstructive pulmonary disease of varying severity: results of the Russian trial].

https://arctichealth.org/en/permalink/ahliterature136824
Source
Ter Arkh. 2010;82(10):46-51
Publication Type
Article
Date
2010
Author
I E Stepanian
N G Khmel'kova
B. Belin-Atarac
Source
Ter Arkh. 2010;82(10):46-51
Date
2010
Language
Russian
Publication Type
Article
Keywords
Administration, Inhalation
Bronchodilator Agents - administration & dosage - adverse effects - therapeutic use
Female
Humans
Male
Middle Aged
Nebulizers and Vaporizers
Pulmonary Disease, Chronic Obstructive - drug therapy
Respiration - drug effects
Respiratory Function Tests
Russia
Scopolamine Derivatives - administration & dosage - adverse effects - therapeutic use
Severity of Illness Index
Treatment Outcome
Abstract
To evaluate the efficacy and safety of Spiriva (thiotropium bromide 18 microg for inhalation via a HandiHaler device) in patients with chronic obstructive pulmonary disease (COPD) of all severities in routine clinical practice in Russia.
The study enrolled 407 patients (68 women and 339 men) with COPD who used thiotropium bromide (Spiriva) for 8 weeks. Most (72.3%) of the patients were aged 50-70 years; active smokers were 64.9%; ex-smokers were 27%; smoking duration averaged 38.6 pack-years; Severe, moderate, very severe, and mild COPD was observed in 38.6, 37.3, 18.4, and 5.7%, respectively. By the start of the trial, 305 (74.5%) had received concomitant therapy.
After 8-week thiotropium bromide therapy, there was a significant increase in bronchial patency, as suggested by considerable increments in the postbronchial indices: forced expiratory volume in one second (FEV1) by an average of 290 ml (20.4%) of the baseline level during treatment and forced vital capacity (FVC) by 310 ml (12.1%). By the end of the trial, the mean increase in inspiratory capacity (IC) by 180 ml (8.07%) of the baseline value was indicative of decreased lung hyperinflation in the treated patients. The significant increment in mean FEV1, FVC, and IC was observed in patients with any severity of COPD.
The RUSSE study has indicated that there may be very good results in patients with COPD of any severity and a steady-state positive effect just after 8-week thiotropium bromide treatment. This treatment improves bronchial patency and diminishes lung hyperinflation, thus improving the patients' health status and exercise endurance.
PubMed ID
21341464 View in PubMed
Less detail